ArticleChemical & biomedical imaging2026
Digadoglucitol: A New High Relaxivity MRI Contrast Agent Based on the Dimerization of [Gd(HP-DO3A)] and Activated Intramolecular Catalysis of the Prototropic Exchange.
Article in Chemical & biomedical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Accelerating Proton Exchange in 1,8-Bis(dialkylamino)naphthalene Proton Sponges through Intramolecular Catalysis for CEST MRI.Journal of the American Chemical Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Digadoglucitol is an extracellular macrocyclic dinuclear gadolinium-based contrast agent (GBCA) based on the association of two [Gd-(HP-DO3A)] units conjugated through a spacer containing the glucamine moiety. It displays a relaxivity per Gd that is 2 to 3 times higher than the most currently used GBCAs, allowing the use of reduced doses while ensuring a noninferior image contrast. Its high relaxivity is the result of a rational design aimed at exploiting the intramolecular catalysis of the prototropic exchange of the coordinated -OH groups as well as the second sphere contribution brought about by the presence of the hydroxyl functionalities on glucamine. Digadoglucitol maintains the excellent kinetic and thermodynamic properties of the parent [Gd-(HP-DO3A)] with an SAP/TSAP ratio of 2/3. A HPLC workup yielded three fractions of diastereoisomers based on the chirality of the 2-hydroxypropyl pendants with similar relaxometric and stability properties. From pH 5 to 9, the deprotonated glucamine nitrogen acts as base to catalyze the prototropic exchange of the coordinating -OH group bringing an enhancement of 1.5-2.0 mM
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.